Leah J. Damon

Signum Biosciences (United States) — United States

Medicine · Health Sciences

13h-index3.1kcitations51works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholangiocarcinoma and Gallbladder Cancer Studies(19), Chronic Myeloid Leukemia Treatments(16), Drug Transport and Resistance Mechanisms(12), Trace Elements in Health(6), Genomics and Chromatin Dynamics(5)

Publications51 total

Abstract LB007: Discovery of a novel molecular glue degrader of Nrf2
Cancer Research·2025
Cellular zinc status alters chromatin accessibility and binding of p53 to DNA
Life Science Alliance·2024· 8 citedOpen Access
Abstract LB164: Inducing immunogenic cell death in difficult-to-treat cancers with an orally-bioavailable GPX4 inhibitor
Cancer Research·2024
Abstract LB169: Using a global reporter on transcript abundance to identify a selective inhibitor of Nrf2 signaling in KEAP1-mutant non small cell lung cancer
Cancer Research·2024
Cellular zinc status alters chromatin accessibility and binding of transcription factor p53 to genomic sites
2023· 1 citedOpen Access
A landscape of response to drug combinations in non-small cell lung cancer
Nature Communications·2023· 52 citedOpen Access
Abstract 2755: Identification of novel GPX4 inhibitors using global transcriptional reporters
Cancer Research·2023
Supplementary Table S6 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Data from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Figure Legends, Figures S1 - S6 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Figure Legends, Figures S1 - S6 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Data from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Table S7 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Data from PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
2023Open Access
Supplementary Table S5 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Table S5 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Data from PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
2023Open Access
Supplementary Data from PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
2023Open Access
Supplementary Table S7 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
Supplementary Table S3 from Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Cyril H. Benes(35), Regina K. Egan(24), Patricia Greninger(23), Mathew J. Garnett(20), Andrew S. Liss(19), Supriya K. Saha(18), John D. Gordan(18), Benjamin P. Kleinstiver(18), Mortada S. Najem(18), Yasutaka Kato(18), Rebecca S. Levin(18), James T. Webber(18), Ultan McDermott(18), Kimberly Rieger‐Christ(18), Travis Sullivan(18), Aram F. Hezel(18), Yusuke Mizukami(18), Lipika Goyal(18), Andrew X. Zhu(18), Kevan M. Shokat(18)